The Kynurenine Pathway in Acute Kidney Injury and Chronic Kidney Disease

Hai Ning Wee\textsuperscript{a} Jian-Jun Liu\textsuperscript{b} Jianhong Ching\textsuperscript{a,c} Jean-Paul Kovalik\textsuperscript{a}
Su Chi Lim\textsuperscript{b,d,e}

\textsuperscript{a}Duke-NUS Medical School, Singapore, Singapore; \textsuperscript{b}Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Singapore; \textsuperscript{c}KK Research Centre, KK Women’s and Children’s Hospital, Singapore, Singapore; \textsuperscript{d}Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore; \textsuperscript{e}Diabetes Centre, Admiralty Medical Centre, Singapore, Singapore

\section*{Keywords}
Kynurenine · Tryptophan · Acute kidney injury · Chronic kidney disease · Uremia · Inflammation

\section*{Abstract}
\textbf{Background:} The kynurenine pathway (KP) is the major catabolic pathway for tryptophan degradation. The KP plays an important role as the sole de novo nicotinamide adenine dinucleotide (NAD\textsuperscript{+}) biosynthetic pathway in normal human physiology and functions as a counter-regulatory mechanism to mitigate immune responses during inflammation. Although the KP has been implicated in a variety of disorders including Huntington’s disease, seizures, cardiovascular disease, and osteoporosis, its role in renal diseases is seldom discussed. \textbf{Summary:} This review summarizes the roles of the KP and its metabolites in acute kidney injury (AKI) and chronic kidney disease (CKD) based on current literature evidence. Metabolomics studies demonstrated that the KP metabolites were significantly altered in patients and animal models with AKI or CKD. The diagnostic and prognostic values of the KP metabolites in AKI and CKD were highlighted in cross-sectional and longitudinal human observational studies. The biological impact of the KP on the pathophysiology of AKI and CKD has been studied in experimental models of different etiologies. In particular, the activation of the KP was found to confer protection in animal models of glomerulonephritis, and its immunomodulatory mechanism may involve the regulation of T cell subsets such as Th17 and regulatory T cells. Manipulation of the KP to increase NAD\textsuperscript{+} production or diversion toward specific KP metabolites was also found to be beneficial in animal models of AKI. \textbf{Key Messages:} KP metabolites are reported to be dysregulated in human observational and animal experimental studies of AKI and CKD. In AKI, the magnitude and direction of changes in the KP depend on the etiology of the damage. In CKD, KP metabolites are altered with the onset and progression of CKD all the way to advanced stages of the disease, including uremia and its related vascular complications. The activation of the KP and diversion to specific sub-branches are currently being explored as therapeutic strategies in these diseases, especially with regards to the immunomodulatory effects of certain KP metabolites. Further elucidation of the KP may hold promise for the development of biomarkers and targeted therapies for these kidney diseases.

© 2021 The Author(s).
Published by S. Karger AG, Basel

This is an Open Access article licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense), applicable to the online version of the article only. Usage and distribution for commercial purposes requires written permission.

Correspondence to:
Jianhong Ching, jianhong.ching@duke-nus.edu.sg
Introduction

Kidney diseases represent a global health issue. Acute kidney injury (AKI) affects up to 1 in 5 hospitalized adult patients [1, 2] and is linked to a 4-fold increase in in-hospital mortality [3]. Chronic kidney disease (CKD) accounted for 1.2 million deaths in 2017 and was the 12th leading cause of death worldwide [4]. Current renal biomarkers such as blood urea nitrogen and creatinine, though functional, are not as sensitive in detecting early disease and do not provide any information on the underlying etiologies of renal damage. The kynurenine pathway (KP) is the primary route for tryptophan (TRP) catabolism, accounting for around 95% of dietary TRP degradation [5]. Physiologically, kynurenine (KYN) metabolites are crucial for energy metabolism and immune modulation. Pathologically, the KP has been implicated in a variety of disorders including Huntington’s disease [6], seizures [7], cardiovascular disease [8], and osteoporosis [9]. However, its involvement in renal disease is seldom discussed. Here, we provide a balanced view of the KP and its metabolites in the pathophysiology of AKI and CKD, potential use as biomarkers, and possible relevance as interventional targets.

Overview of the KP

KP and Its Metabolites

TRP flux into the KP is controlled primarily by the first enzyme(s), namely tryptophan 2,3-dioxygenase (TDO) in the liver and indoleamine 2,3-dioxygenase (IDO) elsewhere in the body [10]. The KP can be further subdivided into 3 branches, as shown in Figure 1.

Nicotinamide adenine dinucleotide (NAD\(^+\)) branch: KYN is converted to 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA), quinolinic acid (QUIN), and finally to NAD\(^+\), which is the preferred end product of the KP [11].

Picolinic acid (PA) branch: In the kidney and liver, KYN may be diverted to a second pathway to produce PA instead. One of the side products is glutaryl CoA, which is metabolized in the Krebs cycle to CO\(_2\) and ATP for energy. Amino-β-carboxymuconate-semialdehyde-decarboxylase (ACMSD) is the enzyme for this branch [12] and is responsible for tipping KP metabolism away from NAD\(^+\) synthesis toward PA production.

Kynurenic acid (KYNA) branch: The third branch of the pathway, leading to the production of KYNA and xanthurenic acid (XA), is mediated by kynurenine ami-

notransferases. This is a minor pathway under physiological conditions likely because of the enzyme kinetics of this metabolic route [10].

KP in Energy Metabolism and Inflammation

The KP is believed to play crucial roles in energy metabolism and inflammation. The KP is the sole de novo NAD\(^+\) biosynthetic pathway, by which humans can derive NAD\(^+\) from dietary amino acids [13]. In normal physiology, the KP is primarily directed toward the production of NAD\(^+\) (via the NAD\(^+\) branch) or glutaryl CoA (via the PA branch) for energy metabolism, as shown in Figure 1.

Mounting evidence supports inflammation as a key driver of TRP influx into the KP and, reciprocally, KP metabolites as key modulators of the inflammatory response. During inflammation, pro-inflammatory cytokines, mainly tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), increase the catabolism of TRP down the KP by inducing IDO expression [14, 15]. This results in an increase in KP metabolites from all sub-branches, including NAD\(^+\) and KYNA, as shown in Figure 1. The increase of flux down the KP during inflammation is believed to serve 2 important purposes – to provide energy for immune responses and to provide a counter-regulatory mechanism to keep inflammation in check. From an evolutionary perspective, activated immune cells require a large amount of energy to fight off pathogen invasion, and hence the KP is activated to produce adequate amounts of NAD\(^+\) for cellular respiration [7]. NAD\(^+\) is also used as co-substrates for sirtuins and poly-ADP ribosylation polymerases, which can protect the host against oxidative stress related to inflammation. Importantly, many of the KP metabolites possess immunoregulatory properties that can mitigate the inflammation response. For example, KYNA is found to reduce pro-inflammatory cytokines [16], while KYN, 3-HK, and HAA can induce the apoptosis of Th1 and natural killer cells [7]. The activation of the KP is found to be essential for immune tolerance in pregnancy and organ transplantation [17, 18], and the immunosuppressive role of KP metabolites has been extensively reviewed [16, 17, 19, 20].

KP in AKI

Definition and Common Etiologies of AKI

AKI is defined as an abrupt deterioration in kidney function (within 7 days), leading to the retention of urea and other nitrogenous waste in the blood [21]. It is a
The Kynurenine Pathway in AKI and CKD

The Kynurenine Pathway in AKI and CKD encompasses multiple etiologies, such as ischemia, sepsis, and drug-induced toxicity. The spectrum of injury ranges from mild to advanced [22], with an in-hospital mortality of up to 60% for severe cases requiring renal replacement therapy [23]. The long-term consequence for survivors includes progression to CKD, end-stage kidney disease (ESKD), and increased risk for cardiovascular diseases and mortality [24].

**KP Metabolites as Potential Biomarkers for AKI**

Most animal studies have shown that the KP is activated in AKI. TRP was reduced and KP metabolites such as KYN, KYNA, and 3-HK were elevated in the plasma [25] and kidney tissue [26] of mice with ischemia/reperfusion-induced AKI. Mice subjected to sepsis-associated AKI showed lower TRP and derangements in KYN, KYNA [27], and QUIN [28] compared to sham controls. Similarly, mice with AKI arising from drug-induced toxicity were found to have higher KYN [29, 30] and KYNA [29] in the blood. An exception is a study which found higher urinary TRP and lower urinary KYNA in newborn rats subjected to gentamycin-induced AKI [31]. One possible reason for this discrepancy is that gentamicin may specifically suppress IDO activity [32]. Mechanistically, the upregulation of KP metabolism during AKI may be explained by the increase in IFN-γ and other pro-inflammatory cytokines. During AKI, the initial kidney damage and cell death evoke an acute inflammatory response involving resident and infiltrating leukocytes [33]. This inflammatory phase is mainly orchestrated and amplified by pro-inflammatory cytokines such as IFN-γ and TNF-α. Since both IFN-γ and TNF-α are strong activators of IDO (the rate-limiting enzyme of the KP), the upregulation of the KP and increase of its metabolites during AKI may be attributed to these pro-inflammatory cytokines. While IDO is generally upregulated, some of the downstream KP enzymes such as kynurenase and quinolinate phosphoribosyltransferase were found to be downregulated in various models of AKI, resulting in further accumulation of the KP intermediates and an impairment of the de novo NAD+ biosynthesis via the KP [34, 35].

In clinical observational studies, plasma and urinary KP metabolites were generally increased in patients with AKI of different etiologies, in agreement with animal data. Additionally, the increase in KP metabolites was correlated with inflammation and occurred early in the disease course. A cross-sectional study found that KYN/TRP ratio (a proxy for IDO or TDO activity) was increased during AKI episodes in transplant patients [36]. A longitudinal study showed that KYNA was increased in septic shock patients with AKI, and the increase was correlated with the inflammatory marker procalcitonin [37]. It is noteworthy that treatment with dialysis reduced plasma KYNA only in survivors but not in non-

**Fig. 1.** KP in health and inflammation.

ACMSD, α-amino-β-carboxymuconate-ε-semialdehyde-decarboxylase; ANA, anthranilic acid; 3-HAA, 3-hydroxyanthranilic acid; 3-HK, 3-hydroxykynurenine; IDO, indoleamine 2,3-dioxygenase; IFN-γ, interferon-gamma; IL-6, interleukin-6; KAT, kynurenine aminotransferases I–III; KMO, kynurenine 3-monooxygenase; KYN, kynurenine; KYNA, kynurenic acid; NAD+, nicotinamide adenine dinucleotide; PA, picolinic acid; QUIN, quinolinic acid; TDO, tryptophan 2,3-dioxygenase; TNF-α, tumor necrosis factor-alpha; TRP, tryptophan; XA, xanthurenic acid; KP, kynurenine pathway.

(Created with BioRender.com.)
survivors, possibly due to persistent inflammation in non-survivors. Another longitudinal study monitored ICU patients with AKI of mixed etiologies. It reported a significant difference in urinary concentrations of TRP, KYN, KYNA, and 3-HAA between early recovering patients and those with late-/non-recovery [38]. In particular, KYNA increased early in the disease and was the single most important predictor of renal recovery on days 1 and 2. By comparison, creatinine levels were not significantly different between the 2 groups on day 1 and only became an important predictor of renal recovery by day 3. In the third longitudinal study, KYNA was part of a multimarker panel of 7 metabolites that predicted the risk of major adverse kidney events over a 28-day period in ICU patients with and without AKI [39]. In the fourth longitudinal study on hospitalized patients with cirrhosis, KYNA, QUIN, and PA were found to be higher in patients who developed AKI [40]. Additionally, KYNA was found to have prognostic value by predicting the progression to dialysis in patients who developed AKI. Current criteria for clinical diagnosis and staging of AKI (e.g., RIFLE, AKIN, KDIGO) are based on changes in serum creatinine and urine output [41]. However, the serum creatinine level is considered an insensitive biomarker for AKI because its rise is often delayed following kidney injury [41, 42]. Therefore, further studies are warranted to examine whether KP metabolites such as KYNA may serve as biomarkers for early detection of AKI.

**KP as Target for Prevention or Treatment of AKI**

The effect of IDO on AKI in preclinical studies appears to have differing results, depending on the models of AKI. In a model of ischemia/reperfusion-induced AKI, the inhibition of IDO, either pharmacologically using 1-methyltryptophan (1-MT) or genetically using IDO knockout mice, reduced the severity of AKI and ameliorated renal fibrosis [43, 44]. This suggests that activation of IDO is deleterious and promotes ischemia/reperfusion (I/R) injury. By contrast, in a model of cisplatin-induced AKI [30], activation of the KP in renal dendritic cells via IDO led to an expansion of immunosuppressive regulatory T cells (Tregs) in the injured kidney and alleviation of AKI, suggesting that the function of the KP in AKI may be cell- and tissue-dependent.

Other studies investigated the consequences of manipulating KP enzymes downstream of IDO, as shown in Figure 2. Interestingly, the shunting of the KP toward the KYNA side branch consistently protected against AKI. Inhibition of the KMO enzyme, which results in diversion of the KP toward KYNA production, conferred significant protection against AKI arising from renal I/R injury [25] and acute pancreatitis [45], as demonstrated by improvement in renal function and histological changes. Similarly, exogenous administration of KYNA protected against AKI induced by renal I/R injury [46, 47]. The protective effects of KYNA may be related to its anti-inflammatory, ROS-scavenging, and antioxidant activities [16].
The proapoptotic effects of QUIN, PA, and 3-HK may also partly explain why shunting of KP toward the KYNA side branch protected against various models of AKI [48, 49]. Unlike the aforementioned KP metabolites, KYNA does not seem to promote apoptosis in renal cells. Additionally, KYNA can inhibit TNF-α production and possesses antioxidant properties related to its ability to scavenge hydroxyl, superoxide anion, and other free radicals [16]. Hence, the diversion toward KYNA production via KMO inhibition may be explored as a potential therapeutic strategy for AKI.

Another interesting target for treatment of AKI is the ACMSD enzyme, which lies at the junction between the NAD+ branch and the PA branch. Inhibition of the ACMSD enzyme, which increased the production of NAD+, protected against AKI in both I/R injury and cisplatin-induced models, as demonstrated by improvement in renal function and histological scores [50]. The increased production of NAD+ is believed to be beneficial by serving as cofactors for renoprotective sirtuins [51] and poly-ADP ribosylation polymerases, which are required for DNA repair [52].

**KP in CKD**

**Definition and Common Etiologies of CKD**

CKD is defined as an abnormality of the kidney structure or function for ≥3 months [41], as diagnosed by abnormal GFR (<60 mL/min/1.73 m²) or persistent proteinuria. The most common types of CKD are diabetic kidney disease, hypertensive nephrosclerosis, and glomerulonephritis [41]. Regardless of etiology, a large proportion of patients with CKD may eventually progress to ESKD.

**Association of KP Metabolites with Onset and Progression of CKD**

KP metabolites have been measured in CKD patients of mixed etiology in both cross-sectional and longitudinal studies. A cross-sectional study found that CKD patients had higher serum levels of IDO, KYN, and lower TRP compared to healthy controls and their KYN/TRP ratios correlated with disease stages [53]. Another cross-sectional study found that KYN/TRP could distinguish CKD patients from non-CKD patients and was independently associated with albuminuria-to-creatinine ratio after adjustment for CKD-related indices [54].

Three large-cohort longitudinal studies found KP metabolites to be increased during the onset of CKD. The first study monitored 1,434 participants with normal baseline eGFR in the Framingham Heart Study for 8 years [55]. It found that KYN and KYNA were associated with incident CKD, even after adjustment for eGFR, age, sex, diabetes, hypertension, and proteinuria at baseline. Inclusion of KYN and KYNA in a multimarker panel of 5 metabolites improved the discrimination and classification of incident CKD. The second study examined the longitudinal associations of metabolites with CKD incidence in 1,104 participants in Augsburg, Germany [56]. KYN/TRP was found to be associated with annual eGFR decline and incident CKD in 7 years’ follow-up. The third study followed 1,741 subjects from Korea over 8 years and found that KYN and KYN/TRP were positively associated with new-onset CKD [57]. Inclusion of KYN and KYN/TRP into a panel of 4 metabolites improved the prediction of new-onset CKD. Collectively, these 3 large-cohort studies demonstrated the potential predictive value of KP metabolites such as KYN and KYNA for incident CKD. It should be noted that KYNA (and possibly KYN) relies on tubular secretion in addition to glomerular filtration for clearance from the serum, which makes them potential markers of non-GFR-related renal function [55]. The potential of KYN to be used as a predictor of CKD across different ethnic populations has been highlighted in a meta-analysis [58]. Out of the 233 metabolites analysed, KYN had the best score as a CKD biomarker.

Two longitudinal studies have studied the association of KP metabolites with risk for CKD progression. The first longitudinal study found no significant differences in plasma TRP, KYN, or KYNA between 40 fast progressors and 40 slow progressors [59]. This study is limited by a small sample size and short follow-up period. The second longitudinal study monitored 3,075 CKD patients for CKD progression (defined as 50% decline in eGFR in a median follow-up of 6.0 years) [60]. Notably, the study measured both plasma and urinary concentrations to compute the kidney clearances of suspected secretory solutes as an estimate of tubular secretion function. The authors found that a lower kidney clearance of KYNA showed the strongest association with CKD progression out of the 11 metabolites monitored, suggesting that kidney clearance of KYNA may provide complementary information to existing measurements of GFR and albuminuria for the assessment of kidney health [60].

**KP in CKD Secondary to Specific Causes**

There were fewer clinical studies on cause-specific CKD and they were mostly cross-sectional studies with relatively small sample size.
Diabetic Kidney Disease

Two cross-sectional studies showed that plasma KYN, KYNA, QUIN [61], and KYN/TRP [62] were increased in patients with diabetic kidney disease (DKD) and correlated with eGFR. Four other observational studies found that KYN levels were positively associated with proteinuria [63, 64] and could distinguish between DKD patients with macroalbuminuria and diabetic patients without albuminuria [65, 66]. A small longitudinal study showed that urinary KYNA could differentiate between progressive albuminuria and non-progressive albuminuria in patients with type 1 diabetes [67]. Immunostaining of kidney sections from DKD animal models revealed higher levels of IDO in the diabetic kidney than in control [68], and the levels of IDO were positively correlated with M1 macrophage and monocytes [69].

Hypertension-Related CKD

KP metabolites have been considered as potential biomarkers for hypertension-related kidney disease. Etiologically, there is a clear distinction between hypertensive nephrosclerosis (kidney damage due to chronic hypertension) and renovascular hypertension (hypertension secondary to kidney diseases). Correlations with KP metabolites have been observed for both conditions. In an observational study, KYN was one of the top 5 metabolites which might discriminate patients with biopsy-proven hypertensive nephrosclerosis from healthy controls [70]. In a rat model of renovascular hypertension, increased levels of KYN, KYNA, 3-HK, and AA and reduced levels of TRP were observed, with KYN independently associated with mean blood pressure [71].

Chronic Glomerulonephritis

In an observational study, KYN was found to be higher in patients with renal failure due to chronic glomerulonephritis as compared to healthy controls [72]. A small pilot study on patients with IgA nephropathy found KYN to be associated with disease severity and ANA to correlate with proteinuria [73]. Interestingly, in a murine model for crescentic glomerulonephritis, KYN/TRP ratio was found to be increased in the serum and renal tissue. Immunohistochemistry revealed upregulation of IDO in glomerulus and renal tubular epithelial cells of the mice [74]. The clinical implication of the finding remains to be elucidated.

Inflammation as the Main Driver of KP Activation in CKD

The defense and repair adaptations after onset of kidney injury can be broadly categorized into hemodynamic and nonhemodynamic changes [41, 75]. In the presence of unresolved injury, several common pathways may converge to perpetuate and exacerbate CKD regardless of the primary causes. The hemodynamic changes in CKD are primarily mediated by the renin-angiotensin-aldosterone system. The primary nonhemodynamic component is chronic inflammation, while renal fibrosis represents a failed wound-healing process of the kidney tissue following persistent injury and unresolved inflammation. CKD-related factors that may induce and/or perpetuate chronic inflammation include advanced glycation end products, vasoactive agents (e.g., angiotensin II), reactive oxygen species, and uremic toxins [75]. These factors can activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), the master regulator of inflammation, and induce the release of pro-inflammatory cytokines TNF-α and IFN-γ, both of which are potent inducers of the KP rate-limiting enzyme IDO. In corollary, several observational studies found high correlations between KP metabolites and inflammation in CKD patients. In a cross-sectional study, KYN, KYNA, QUIN levels, and IDO activity (KYN/TRP ratio as proxy) were positively correlated with inflammatory markers (hsCRP and soluble TNF receptor-1) in CKD patients [76]. In another cross-sectional study, 3-HAA level was independently associated with increased monocyte chemoattractant protein-1 and macrophage inflammatory protein-1β in CKD patients [77]. A cross-sectional study on ESKD patients found ANA to be significantly correlated with ferritin, a commonly used inflammatory marker in hemodialysis [78].

The Potential Protective Role of KP in CKD – Effects of KP Activation on Intrarenal Inflammation and Fibrosis

In vivo preclinical studies consistently demonstrated a protective role for KP and its metabolites in glomerulonephritis [74, 79–81]. The protection conferred by KP activation seems to be related to its anti-inflammatory effects, especially its ability to induce phenotype switching of the T lymphocytes.

T lymphocytes are known to differentiate into distinct phenotypes with opposing functions during the inflammatory and repair phases, driven mainly by cytokines such as IFN-γ and IL-4. In a mouse model of crescentic glomerulonephritis [74], the pharmacological inhibition of IDO by 1-MT aggravated the kidney disease, as shown by increased glomerular crescent formation, accumulation of CD4+ T cells and macrophages in renal tissue. Moreover, 1-MT-treated mice had higher levels of IFN-γ.
The Kynurenine Pathway in AKI and CKD

(IDO agonist) and lower IL-4 (Th2 cytokine), suggesting that IDO is important in maintaining the Th1/Th2 balance during crescentic glomerulonephritis. In a mouse model of IgA nephropathy [80], the administration of the IDO inhibitor 1-MT worsened renal injury, increased Th17-related cytokine expression, and increased the Th17/Tregs ratio in kidney tissues. Conversely, the administration of either the IDO agonist ISS-ODN [80] or dendritic cells with overexpression of IDO [81] protected IgA nephropathy mice against renal injury, reduced Th17-related cytokines, and reduced the Th17/Tregs ratio in the kidney. These data suggest that IDO may confer protection against IgA nephropathy by regulating the Th17/Tregs ratio in the kidney. In a mouse model of anti-glomerular basement membrane glomerulonephritis (anti-GBM GN), the knockout of IDO gene increased disease severity and mortality, whereas the induction of IDO gene protected the mice against antibody-mediated damage to the kidney and improved renal function [82]. In another study, treatment with 3-HK attenuated glomerular immune infiltrates, reduced pro-inflammatory cytokines, improved renal function, and increased survival in a mouse model of anti-GBM GN [83]. In a rat model of anti-GBM GN, treatment by either 3-HAA or 3-HK attenuated the kidney disease, improved renal function, reduced glomerular histological injury, and lowered renal infiltration of CD4+ T cells and macrophages [79]. This was associated with increased apoptosis and decreased proliferation of splenic CD4+ T cells in vivo. The splenic T cells from 3-HAA- or 3-HK-treated rats also exhibited increased Th2 cytokines (IL-4, IL-10) and decreased Th1 cytokines (IFN-γ, IL-12) ex vivo. These data suggest that KP metabolites such as 3-HAA or 3-HK may protect against anti-GBM GN by inducing an immune switch from Th1 to Th2 phenotype. Taken together, the experimental findings highlight the key immunosuppressive roles of the KP and its metabolites in various forms of glomerulonephritis.

Intrarenal fibrosis is an important pathway leading to progressive loss of kidney function. IDO [84] and KP metabolites such as KYN and KYNA [85, 86] were found to be increased during renal fibrosis in the CKD model.
induced by unilateral ureteral obstruction. Further experiments using tubular cell culture showed that IDO was increased after cells were exposed to TGF-β1 [84]. In turn, the inhibition of IDO by 1-MT exacerbated TGF-β1-induced epithelial-to-mesenchymal transition, which is believed to be part of the fibrotic “repair” mechanism that has gone awry due to sustained renal injury and non-resolving inflammation [87]. The findings showed that increased IDO during renal fibrogenesis may be a compensatory response that has a renoprotective effect by reducing epithelial-to-mesenchymal transition.

Mechanisms of Immunosuppression Arising from KP Activation and Potential for Therapies

Mechanistically, the activation of the KP in antigen-presenting cells, particularly the dendritic cells, is believed to promote an immunosuppressive microenvironment for the T cells through the combined effects of KP metabolites accumulation and TRP depletion, as shown in Figure 3. First, the activation of IDO in dendritic cells and subsequent production of KYN were found to promote the generation of Tregs from naïve T cells [88–90], while blocking their conversions to pro-inflammatory Th17-like phenotypes [91, 92]. Second, the increase in proapoptotic KP metabolites such as 3-HAA and QUIN may directly induce apoptosis in the activated T cells [93, 94]. Third, the depletion of TRP from the local environment may inhibit T-cell proliferation [95] and sensitize T cells to apoptosis [96].

Interestingly, experimental studies suggest that IDO activation may be a secondary mechanism that contributes in part to the therapeutic effects of T-cell costimulation blocker Cytotoxic T lymphocyte-associated antigen-4-immunoglobulin (CTLA-4-Ig) and its 2 commercially available drugs – abatacept and belatacept. The inhibition of IDO using either 1-MT or gene-knockout was found to abrogate the immunosuppressive effects of CTLA-4-Ig in various animal models of organ and tissue transplants [97–100]. Abatacept was found to block rheumatoid factor-mediated cytokine production in human macrophages in an IDO-dependent manner in vitro [101]. CTLA-4-induced activation of IDO/TRP pathway was shown to inhibit osteoclast differentiation [102], which may explain the improvement of bone mineral density observed in rheumatoid arthritis patients taking abatacept [103]. Patients receiving belatacept showed greater amounts of peripheral blood CD16+/IDO+ cells and Tregs on graft biopsies than those under cyclosporine treatment [104, 105]. Notably, abatacept has been approved by FDA for the treatment of rheumatoid arthritis [106], while belatacept has been approved by FDA for use as an immunosuppressive therapy to prevent kidney allograft rejection [107]. Additionally, several case reports showed abatacept to have mixed success in the treatment of glomerular diseases such as minimal change disease [108, 109] and focal segmental glomerulosclerosis [110–113]. A phase II trial is currently underway to evaluate the use of abatacept in adults and children with minimal change disease and focal segmental glomerulosclerosis [114]. Together, these promising results highlight the relevance of IDO and KP activation in immunosuppression.

KP in Blood Pressure Control

The most well-studied KP metabolite for blood pressure control is KYNA, which was shown to be a hypotensive agent acting in the central nervous system [115]. The site of action for KYNA was localized to rostral ventrolateral medulla (RVLM), also known as the vasomotor center of the brain [116]. Microinjection of KYNA into RVLM reduced blood pressure in rat models of renovascular hypertension [117–119] and polycystic kidney disease [120]. Interestingly, the blood pressure-lowering effects of KYNA were blunted in rats pretreated with captopril [118] or with overexpression of ACE2 in the RVLM [121]. This suggests that the blood pressure-lowering effects of KYNA may involve interactions among central renin-angiotensin-aldosterone system, RVLM, and its sympathetic outflow, but the exact pathway requires further elucidation. XA was reported to possess vasodilating effects and plays a role in inflammation-induced hypertension [122], although its effects on blood pressure control in CKD have not been studied. Additionally, 2 XA derivatives demonstrated natriuretic effects [123, 124]. Further studies are warranted to examine whether KYNA and XA can alter CKD pathogenesis and progression by regulating blood pressure.

KP Metabolites as Uremic Solutes in Advanced Stages of CKD and ESKD

In 2003, the European Uremic Toxin Work Group defined 90 compounds as uremic retention solutes [125, 126]. Based on their chemical and protein-binding properties, they are divided into 3 categories: water-soluble, low-molecular-weight compounds (<500 Da), large-molecular-weight compounds (500–5,000 Da), and protein-bound compounds [125, 126]. KP metabolites such as KYN, KYNA, and QUIN were included in the list as protein-bound compounds. The concentrations of KYNA
The Kynurenine Pathway in AKI and CKD

The Kynurenine Pathway in AKI and CKD [128, 129], indicating that the etiologies of CKD KYNA was strongly associated with underlying causes of function, respectively. Interestingly, the net clearance of 15 times higher in uremic stage compared to normal renal [127] and QUIN [125] were reported to be 27.6 times andods [134–137], as summarized in online supplementary man samples include mass spectrometry, high perfor- mance-liquid chromatography, and colorimetric meth- ods for measuring KP metabolites in human samples include mass spectrometry, high performance-liquid chromatography, and colorimetric methods [134–137], as summarized in online supplementary Table 1 (see www.karger.com doi/10.1159/000519811 for all online suppl. material). Further development of high-throughput analytical platforms including enzymatic methods [136] may hold promise for the clinical adoption of KP metabolites as biomarkers for monitoring of CKD.

KP Metabolites and Vascular Complications of Advanced CKD and ESKD

The role of the KP in various CKD complications has been reviewed elsewhere [138]. Here, we briefly discuss the role of KP metabolites in thrombosis and atherosclerosis. CKD is known to increase the risk of thrombosis by at least 2-fold [139], while the uremic state accelerates the development of atherosclerosis [140]. According to Virchow’s triad, hypercoagulability and atherosclerosis are important factors for thrombus formation [141], and they contribute to the prothrombotic condition in CKD patients [142, 143].

KP metabolites have been associated with hypercoagulability in CKD patients. Cross-sectional studies of CKD patients consistently showed positive correlations between KP metabolites such as KYN, 3-HK, and QUIN and hemostatic mediators such as von Willebrand factor [144, 145], tissue factor [146, 147], and prothrombin factor 1 + 2 [146]. A longitudinal study found that CKD patients who developed arteriovenous thrombosis within a 6-week period after arteriovenous fistula creation had higher baseline KYN and tissue factor than those without thrombosis [148]. By contrast, the association of KP metabolites with fibrinolysis is less clear. One study showed that 3-HK and QUIN were positively correlated with plasmin-antiplasmin complexes in ESKD patients with hyperfibrinolysis [149]. Another study showed that ANA was positively correlated with urokinase-type plasminogen activator in the early stages of CKD, whereas it was inversely related to tissue plasminogen activator and plasminogen activator inhibitor-1 in advanced stages of CKD [150]. The mixed findings on the correlation between KP metabolites and fibrinolysis markers may reflect the complex derangements of the fibrinolytic system in the set-tings of CKD, which is influenced by upstream mechanisms including hypercoagulation, renal damage, and inflammation.

KP metabolites have also been associated with atherosclerosis and vascular inflammation in CKD patients. Cross-sectional studies of patients with ESKD consistently showed KP metabolites such as KYN, 3-HK, and QUIN to be positively correlated with intima-media thickness and inflammatory markers [145, 151]. An increase in the KYN/TRP ratio was found to be associated with larger carotid plaques, decreased ankle-brachial pressure index, and increased carotid artery intima-media thickness and inflammation in hemodialysis patients [152]. In 2 cross-sectional studies on uremic patients, KP metabolites such as KYN, KYNA, and ANA were shown to be positively correlated with soluble forms of intercellular adhesion molecule-1 and vascular cell adhesion protein-1 (VCAM-1) [145, 153], which are indicative of vascular inflammation.

Despite findings from these correlational studies, our present understanding of the role of the KP in vascular disease is largely extrapolated from studies in non-CKD models [154], which suggest that the KP and its metabo-lites may play a protective, anti-inflammatory role in ath-erosclerosis. For example, in atherosclerosis-prone ApoE (−/−) mice, the inhibition of IDO, either through IDO gene deletion [155] or pharmacologically using 1-MT [156], was found to accelerate atherosclerotic plaque development and worsen vascular inflammation (i.e., higher VCAM-1 expression, elevated pro-inflammatory cytokines, increased CD68 + macrophage infiltration). These changes were ameliorated by either an orally active synthetic derivative of ANA [155] or administration of 3-HAA [156]. Conversely, activation of the IDO/Tregs axis by tolerogenic dendritic cells in hyperlipidemic mice led to increased levels of KYN in atherosclerotic plaques, reduced atherosclerosis, and reduced vascular inflam-
mation (i.e., lower VCAM-1 expression, lower CD68 + macrophage infiltration) [157]. On the other hand, KP metabolites may promote thrombosis due to their aryl hydrocarbon receptor (AhR) agonist activities. In a murine model of post-vascular injury thrombosis, the exogenous administration of KYN was found to worsen thrombosis in an AhR-dependent manner [148]. It should be noted that these data on KP metabolites and atherosclerosis or thrombosis in non-CKD settings may not extrapolate well to the CKD population. Given that KP metabolites have been associated with several important biological pathways (e.g., AhR agonist activities, immunosuppressive activities), it is reasonable to postulate that the KP also plays an important role in vascular complications in the setting of CKD. The exact role of the KP in CKD-related vascular abnormalities warrants further study.

**Perspective on the Role of the KP in Dysbiosis and Microbe-Host Interactions**

**CKD Is Associated with Dysbiosis**

Increasing evidence suggests that dysbiosis (microbiota dysregulation) may perpetuate CKD and its underlying inflammation. CKD-related factors such as accumulation of intestinal urea, diet restriction, and frequent antibiotic usage are believed to alter microbiota composition and cause dysbiosis in CKD patients [158–160]. Dysbiosis in CKD is often characterized by an overgrowth of pathobionts from the *Enterobacteriaceae* family and decrease of symbionts from the *Bifidobacteriaceae* and *Lactobacillaceae* families [161–164]. This is believed to promote a pro-inflammatory intestinal microenvironment [165, 166]. The ensuing vicious cycle of local intestinal inflammation and increased epithelial barrier dysfunction (“leaky gut”) enables endotoxins and microbial metabolites to translocate into the host’s bloodstream, contributing to systemic inflammation in CKD patients [167, 168]. In addition, the accumulation of microbial-derived metabolites such as indoxyl sulfate in the bloodstream is believed to increase cardiovascular and renal toxicity in CKD patients [160, 169]. In view of this, researchers have explored the therapeutic use of probiotics containing *Bifidobacteria* and *Lactobacillus* species in CKD patients, and these probiotics have been shown to significantly reduce inflammation and improve renal functions [170–174].

**KP Is Altered by the Gut Microbiota**

The key role of the gut microbiota in stimulating IDO and activating the KP was demonstrated in several studies. Germ-free mice showed lower KYN/TRP ratio compared to conventional mice [175]. This trend was reversed by the colonization of germ-free mice with conventional mice fecal microbiota [176]. The IDO expression in the colon and immune cells were generally upregulated in the presence of gut bacteria from the genera *Bifidobacteria*, *Lactobacillus*, *Bacillus*, and *Clostridium* [177–182], though specific species such as *Lactobacillus johnsonii* showed inhibitory effects [183]. In terms of microbe-host dynamics, the prevailing view from these studies is that the microbes and their components may stimulate host IDO enzyme, leading to an upregulation of the KP and its metabolites in the host body. For example, the exopolysaccharide from *Bacillus subtilis* was found to induce IDO in host dendritic cells [182]. Interestingly, an in vivo study using a CKD rat model reported a positive correlation between the plasma KP metabolites (KYN and 3-HK) and gut bacteria from the genera *Oscillibacter*, *Blautia*, and *Intestimimonas*. These gut bacteria were predicted to possess IDO genes using PICRUSt database based on ancestral state reconstruction. This suggests that the gut bacteria may play a key role by directly producing KP metabolites. However, one has to be cautious when interpreting bacterial genes of the KP enzymes. While the KP is the primary de novo pathway for NAD+ synthesis in eukaryotes and their enzymes are constitutively expressed in mammals, most bacteria depend instead on the aspartate pathway for de novo NAD+ synthesis and their KP-related genes may play a lesser role compared to mammals [184, 185]. Indeed, a study found that the catalytic efficiencies of IDO in certain bacteria were much lower than their mammalian homologs and are unlikely to contribute to TRP metabolism [186]. Further experiments are required to ascertain whether gut bacteria from genera *Oscillibacter*, *Blautia*, and *Intestimimonas* can produce substantial amount of the KP metabolites. By extension, further work is also needed to delineate the specific contribution of microbe and the host cells for the production of the KP metabolites during CKD-related dysbiosis.

**KP Modulates Host Immunity and Microbiota Composition, Which May Indirectly Affect CKD Pathogenesis and Progression**

The interaction between gut microbiota and host immune system is multifaceted [187]. Functionally, the KP was found to be a key player in mediating the microbe-host immunity interplay. The activation of the KP via IDO was crucial for mediating the immunomodulatory effects of symbionts *Bifidobacteria* and *Lactobacillus* spe-
cies in models of inflammatory and allergic diseases such as ulcerative colitis [177, 181], rheumatoid arthritis [177], atopic dermatitis [177], allergic asthma [188], and autoimmune Type 1 diabetes [179]. In these studies, supplementation with probiotics containing these 2 symbionts led to an upregulation of IDO expression or increase in KYN/TRP ratio, reduction of inflammation, and alleviation of disease severity. Mechanistically, the protective effects conferred by the probiotics involved the modulation of Tregs/Th17 balance via an upregulation of IDO in immune cells such as dendritic cells [177, 179, 181, 189]. Interestingly, a study highlighted IDO-dependent expansion of Tregs in the intestinal mucosa as an important aspect of microbe-host crosstalk during development and may be associated with resistance against inflammatory and allergic diseases later in adulthood [178]. Moreover, Lactobacillus-induced elevation of KYN in the gut epithelium was found to increase Type 3 innate lymphoid cells, a specialized gut immune cell required for the maintenance of gut mucosal homeostasis [190]. KYN was also found to protect against colitis by reducing intestinal permeability and promoting epithelial wound healing [191]. Collectively, these studies suggest that the KP and its metabolites may be key mediators of the host-microbe symbiosis that maintains gut and systemic immunity. Further work is required to validate these findings in CKD settings.

The relationship between the gut microbes and hosts is bidirectional. Besides influencing host immunity, the activation of the KP may modulate certain TRP-metabolizing bacteria. The activation of the KP was shown to limit TRP availability and reduce indole-producing bacteria and their metabolites, such as indoxyl sulfate [192] and indole-3-acetic acid [193, 194]. The effects of indole metabolites in CKD have been reviewed elsewhere [195–198]. Currently, the carbonaceous adsorbent AST-120 is used to reduce indoxyl sulfate production in CKD patients [199]. The activation of the KP may represent another strategy to reduce indole metabolites in CKD patients.

**Conclusion**

The KP is the major pathway for TRP catabolism. During inflammation, the activation of the KP via its rate-limiting enzyme IDO is driven by pro-inflammatory cytokines such as IFN-γ and TNF-α. Given that immune activation and the resultant elevation of pro-inflammatory cytokines underlie the pathogenesis and progression of AKI and CKD, it is not unexpected to see that the KP is activated in clinical and animal studies of these diseases. KP metabolites are currently being explored as early biomarkers for AKI and uremic markers for adequacy of dialysis in ESKD patients. Since the turnover of KP metabolites such as KYNA is highly determined by tubular excretion, they may serve as promising biomarkers for tubular function, to complement glomerular filtration markers currently used in diagnosis and prognosis of kidney diseases.

The therapeutic potential of the KP in kidney diseases warrants future research. Activation of the KP is often regarded as a counter-regulatory mechanism to inflammation. Thus, the KP is found to confer protection in kidney diseases where inflammation is the primary insult. In vivo studies consistently demonstrated a protective role for the KP and its metabolites in various models of glomerulonephritis by slowing T-cell proliferation and reducing activation of pro-inflammatory T-cell phenotypes (Th1 and Th17), while enhancing the switch to immunosuppressive T-cell phenotypes (Th2 and Tregs). Interestingly, some studies have demonstrated that shunting the KP toward certain side branches can confer significant protection against AKI. This may be a possible approach to exploit the renoprotective effects of specific components of KP.

Besides immunomodulatory activity, KP metabolites possessed other biological functions, including hypotensive, antioxidant, and AhR agonist effects. Given the complexities of kidney diseases and multi-organ involvement in CKD complications, the interpretation of the biologic activities of KP metabolites may be context-dependent and should be done with caution. Further loss-of-function/gain-of-function studies are needed to tease apart how individual metabolites contribute to and alter the course of kidney diseases and their complications. The role of the KP in CKD-related dysbiosis also warrants further research.

This review contextualizes the role of the KP and its metabolites in AKI and CKD. Emerging data support the KP and its metabolites as promising candidates for developing relevant biomarkers and targeted therapies for these kidney diseases.

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.
Funding Sources

Dr. S.C. Lim was funded by the Singapore National Medical Research Council (CSA-INV/0020/2017). Dr. J.-J. Liu acknowledges funding support from KTPH STAR 20201.

Author Contributions

H.N.W. wrote the first draft and edited the manuscript. J.-J.L., J.C., J.P.K., and S.C.L. were responsible for conceptualization, critical review, and editing of the manuscript. All authors have read and approved the final manuscript.

References

1 Mehta RL, Cerda J, Burdmann EA, Tonelli M, García-Gayos G, Lha V, et al. International society of nephrology’s 0 by 25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015;385(9987):2616–43.
2 Hoste EAJ, Keluum JA, Selby NM, Zarbok A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018;14(10):607–25.
3 Sawhney S, Fraser SD. Epidemiology of AKI: utilizing large databases to determine the burden of AKI. Adv Chronic Kidney Dis. 2017 Jul;24(4):194–204.
4 Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020;16(5):251–1.
5 Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017;357(6349):eaaf9794.
6 Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):467–77.
7 Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25(1):131–47.
8 Polyzos KA, Ketelhuth DF. The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease. An emerging field. Handb Humasei. 2015;35(02):128–36.
9 Al Saedi A, Sharma S, Summers MA, Nurgali K, Duque G. The multiple faces of tryptophan metabolism in bone biology. Exp Gerontol. 2020;129:110778.
10 Badawy AA. Tryptophan metabolism: a versatile approach multiple targets for pharmacological intervention. Egypt J Basic Clin Pharmacol. 2019;9:10.
11 Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017;357(6349):eaaf9794.
12 Pucci L, Perozzi S, Cinamadore F, Orsman- do G, Raffaelli N. Tissue expression and biochemical characterization of human 2-amino-3-carboxyoxymono-6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism. FEBS J. 2007 Feb;274(3):827–40.
13 Castro-Portuguez R, Sutphin GL. Kynurenine pathway, NAD+ synthesis, and mitochondrial function: targeting tryptophan metabolism to promote longevity and healthspan. Exp Gerontol. 2020;132:110841.
14 Robinson CM, Hale PT, Carlin JM. The role of IFN-γ and TNF-α-responsive regulatory elements in the synergistic induction of indoleamine 2,3-dioxygenase. J Interferon Cytokine Res. 2005;25(1):20–30.
15 O’Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, et al. Interferon- and tumor necrosis factor mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus calmette-guerin. J Neurosci. 2009;29(13):4200–9.
16 Wirthgen E, Hoeflich A, Rebl A, Günther J. Kynurenic acid erases the Janus-faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions. Front Immunol. 2018;8(1957):1957.
17 Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm. 2012;119(2):197–209.
18 Zulpaite R, Miknevičius P, Leber B, Strupas K, Stieger P, Schemmer P. Tryptophan metabolism via kynurenine pathway: role in solid organ transplantation. Int J Mol Sci. 2021;22(4):1921.
19 Mellor AL, Lemos H, Huang L. Indoleamine 2,3-dioxygenase and tolerance: where are we now? Front Immunol. 2017;8:360–0.
20 Wu H, Gong J, Lioy I. Indoleamine 2,3-dioxygenase regulation of immune response (Review). Mol Med Rep. 2018;17(4):4687–73.
21 Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006;17(6):1503.
22 Rahman M, Shad F, Smith MC. Acute kidney injury: a guide to diagnosis and management. Am Fam Physician. 2012;86(7):631–9.
23 Tao Li PK, Burdmann EA, Mehta RL. Acute kidney injury: global health alert. Kidney Int. 2013;83(1):114–7.
24 Cerda J, Liu KD, Cruz DN, Jaber BL, Koyner JL, Heung M, et al. Promoting kidney function recovery in patients with AKI requiring RRT. Clin J Am Soc Nephrol. 2015 Oct;7(10):1859–67.
25 Zheng X, Zhang A, Binnie M, McGuire K, Webster SP, Hughes J, et al. Kynurenine biosynthetic impairment in acute kidney injury: a guide to diagnosis and management. Am J Physiol Renal Physiol. 2021;320(5):F984–F1000.
26 Zhang F, Wang Q, Xia T, Fu S, Tao X, Wen Y, et al. Diagnostic value of plasma tryptophan and symmetric dimethylarginine levels for acute kidney injury under continuous veno-venous haemofiltration. Inflammation. 2014 Feb;37(1):223–34.
The Kynurenine Pathway in AKI and CKD

41 Gilbert S, Weiner DE. National kidney foundation primer on kidney diseases e-book: Elsevier Health Sciences; 2013.

42 Mehta RL. Timed and targeted therapy for NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns. Reversing renal insufficiency: a possible link between chronic kidney disease and its correlation with inflammation and uraemic symptoms. Adv Exp Med Biol. 1999;467:759–86.

43 Kalantari S, Nafar M, Samavat S, Parvin M. I H NMR-based metabolomics study for identifying urinary biomarkers and perturbed metabolic pathways associated with severity of IgA nephropathy: a pilot study. Magn Reson Chem. 2017;55(8):693–9.

44 Hou W, Li S, Wu Y, Du X, Yuan F. Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis. Clin Exp Immunol. 2009 May;156(2):363–72.

45 Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F, et al. Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes Endocrinol. 2016;4(4):360–73.

46 Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pchowski R, Hasper D, et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant. 2009 Jun;24(6):1901–8.
83 Clement CC, D’Alessandro A, Thangaswamy L, Chen L, Chen DQ, Liu JR, Zhang J, Vaziri ND, Pawlak K, Kowalewska A, Mysliwiec M, Pawlak-Bozec A, Zaiss MM, Kagwiria R, Voll R, Meyer J. Summary of the US FDA approval of belatacept. Am J Transplant. 2012;12(3):554–62.

98 Furuzawa-Carballeda J, Parikh S, Ayoub I, Rovin B, Nadasdy T, Hebert L. Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept. Clin Nephrol. 2018;89(5):376.

104 Furuzawa-Carballeda J, Lima G, Uribe-Urte N, Arroela-Guerra JM, Reyes-Acevedo R, Vilatoba M, Lopez-Puthenpura MM, Tissie talks: immunophenotype of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years. Clin Exp Immunol. 2019 Aug;207(2):250–61.

114 Trachtman H, Gips JN, Gilmore DS, Somers M, Spino T, Uribe-Uribe NO, Arroela-Guerra JM, Reyes-Acevedo R, Vilatoba M, Lopez-Puthenpura MM, Tissie talks: immunophenotype of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years. Clin Exp Immunol. 2019 Aug;207(2):250–61.
The Kynurenine Pathway in AKI and CKD

115 Malkiewicz MA, Szarmach A, Sabisz A, Cubala WJ, Szurowska E, Winklewski PJ. Blood-brain barrier permeability and physical exercise. J Neuroinflammation. 2019; 16(1):15–6.

116 Kumagai H, Oshima N, Matsuura T, Iigaya T, et al. Importance of rostral ventrolateral medulla neurons in determining effrent sympathetic nerve activity and blood pressure. Hypertens Res. 2012; 35(2):132–41.

117 Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension. 1991;17(5):707–19.

118 Carvalho TH, Bergamaschi CT, Lopes OU, Ximenes AP, et al. Median preoptic nucleus excitatory neurotransmitters in the maintenance of hypertensive state. Brain Res Bull. 2018 Sep;142:207–15.

119 Verma AA, de Mello ABS, Dos Santos Moreira MC, Rodrigues KL, Lopes PR, Xavier CH, et al. Median preoptic nucleus excitatory neurotransmitters in the maintenance of hypertensive disease. J Hypertens. 2019 Jan;37(1):109–15.

120 Wang YK, Shen D, Hao Q, Yu Q, Wu ZT, Deng Y, et al. Overexpression of angiotensin-converting enzyme 2 attenuates tonic-active glutamatergic input to the rostral ventrolateral medulla in hypertensive rats. Am J Physiol Heart Circ Physiol. 2014 Jul 15;307(2):H182–90.

121 Fazio F, Carrizzo A, Lionetto L, Damato A, Carvhalo TB, Gomes LM, et al. Vasorelaxing action of the kynurenine metabolite, xanthurenic acid: the missing link in endothoxin-induced hypotension? Front Pharmacol. 2017;8(241):214.

122 Cain CD, Schroeder FC, Shankel SW,Mitchell-McCoy S, Lechtler M, Bricker NS. Identification of xanthurenic acid 8-O-beta-D-glucoside and xanthurenic acid 8-O-sulfate as human natriuretic hormones. Proc Natl Acad Sci USA. 2007;104(45):17873–8.

123 Hoffman A, Okun-Gurevich M, Ovcharenko E, Goltsman I, Karram T, Cain C, et al. Renal effects of a novel endogenous natriuretic agent xanthurenic acid 8-O-beta-D-glucoside in rats. Physiol Rep. 2013;1(6):e000015.

124 Vanholder R, De Smet R, Glorieux G, Arقيلés A, Bauemerstein U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934–43.

125 Ma YR, Xin MY, Li K, Wang H, Rao Z, Liu TX, et al. An LC-MS/MS analytical method for the determination of uremic toxins in patients with end-stage renal disease. J Pharm Biomed Anal. 2020 Aug 17;191:113551.

126 Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258–70.

127 Grams ME, Tin A, Rebholz CM, Shafi T, Köttgen A, Perrone RD, et al. Metabolomic alterations associated with cause of CKD. Clin J Am Soc Nephrol. 2017;12(11):1787–94.

128 Wang K, Zelnick LR, Hoofnagle AN, Chen Y, de Boer H, Himmelfarb J, et al. Differences in proximal tubular solute clearance across common etiologies of chronic kidney disease. Nephrol Dial Transplant. 2019 Jul 25.

129 Pawlak D, Pawlak K, Malsyzo J, Mysliwiec M, Buczkow. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol. 2001;33(2):199–204.

130 Rhee EP, Souza A, Farrell L, Pollak MR, Lewis GD, Steele DJ, et al. Metabolite profiling identifies markers of uremia. J Am Soc Nephrol. 2010;21:1041–51.

131 Yilmaz N, Ustundag Y, Kivrak S, Kahveciglu S, Celik H, Kivrak I, et al. Serum indoleamine 2,3-dioxygenase and tryptophan and kynurenine ratio using the UPLC-MS/MS method, in patients undergoing peritoneal dialysis, hemodialysis, and kidney transplantation. Ren Fail. 2016 Sep;38(8):1300–9.

132 van Gelder MK, Middel IR, Vernooij RWM, de Rooij SJ, Cecconi M, Maseerew, et al. Protein-bound uremic toxins in hemodialysis patients relate to residual kidney function, are not influenced by convective transport, and do not relate to outcome. Toxins. 2020;12(4):234.

133 Sarkar SA, Wong R, Hackl SI, Moua O, Gill RG, Wiseman A, et al. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes. 2007;56(1):72–9.

134 Fazio F, Carrazzo A, Lionetto L, Damato A, Capocci L, Ambrosio M, et al. Vasorelaxing action of the kynurenine metabolite, xanthurenic acid: the missing link in endotoxin-induced hypotension? Front Pharmacol. 2017;8(241):214.

135 Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010;6(12):732.

136 El-Gengaihy AE, Abdelkafi SI, Kirmaji FN, Qurashi AI. 6.34 – thrombolytics. In: Taylor JB, Triggle DJ, editors. Comprehensive medicinal chemistry II. Oxford: Elsevier; 2007. p. 763–81.

137 Shashar M, Francis J, Chaitalia V. Thrombosis in the urmic milieu-emerging role of “thromboleme”. Semin Dial. 2015;28(2):198–205.

138 Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol. 2018;14(5):337.

139 Pawlak K, Domaniowski T, Mysliwiec M, Pawlak D. Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease. Thromb Res. 2009 Sep;124(4):452–7.

140 pawlak K, Mysliwiec M, Pawlak D. Kynurenine pathway – a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv Med Sci. 2010;55(2):196–203.

141 Pokal K, Mysliwiec M, Pawlak D. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uremac patients. Thromb Haemost. 2009 Jul;102(1):49–55.

142 Koschallana VA, Shashar M, Alouisi F, Shivanna S, Rijal K, Belghasem ME, et al. Uremic solute-aryl hydrocarbon receptor-tissue factor axis associates with thrombosis after vascular injury in humans. J Am Soc Nephrol. 2018;29(3):1063–72.

143 Pawlak K, Buraczewska-Buczkow A, Mysliwiec M, Pawlak D. Hyperfibrinolyisis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment. Am J Med Sci. 2010;339(1):5–9.

144 Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Pawlak D. Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis. 2009 Jun;204(2):561–6.

145 Kato A, Suzuki Y, Suda T, Suzuki M, Fujie M, Takita T, et al. Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients. Hemodial Int. 2010;14(4):418–24.
153 Pawlak K, Kowalewska A, Mysliwiec M, Pawlak D. Kynurenic acid and its metabolites kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion molecules and oxidative status in patients with chronic kidney disease. Am J Med Sci. 2009 Oct;338(4):293–300.
154 Song P, Ramprasaath T, Wang H, Zhou MH. Abnormal kynurenic pathway of tryptophan catabolism in cardiovascular diseases. Cell Mol Life Sci. 2017;74(16):2899–916.
155 Cole EF, Aciolo N, Cribbs AP, Goddard ME, Park I, Green P, et al. Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. Proc Natl Acad Sci USA. 2015;112(42):13033–8.
156 Polyzos KA, Ovchinnikova O, Berg M, Baumgartner R, Agardh P, Pirault J, et al. Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in ApoE−/− mice. Cardiovasc Res. 2015;106(2):295–302.
157 Forteza MJ, Polyzos KA, Baumgartner R, Suur BE, Musbacher M, Johansson DK, et al. Activation of the regulatory T-cell/indole-2,3-dioxygenase axis represses vascular inflammation and atherosclerosis in hyperlipidemic mice. Front Immunol. 2018;9:950.
158 Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 2013;83(6):1010–6.
159 Koppe L, Mafra D, Fouque D. Probiotics and kidney disease. Kidney Int. 2015;88(5):958–66.
160 Meijers B, Evenepoel P, Anders HJ. Intestinal microbe and fitness in kidney disease. Nat Rev Nephrol. 2019;15(9):531–45.
161 Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(3):308–15.
162 Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease-producing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–7.
163 Sampaio-Maia B, Simões-Silva L, Pestana M, Araujo R, Soares-Silva IJ. The role of the gut microbiome on chronic kidney disease. Adv Appl Microb. 2016;96:65–94.
164 Jiang S, Xie S, Li D, Wang P, He H, Zhang T, et al. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Sci Rep. 2017;7(1):2870–0.
165 Sabatino A, Regolisti G, Brusasco I, Cabassi A, Morabito S, Fiaccardi E. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant. 2014;30(6):924–33.
166 Lau WL, Kalantar-Zadeh K, Vaziri ND. The gut as a source of inflammation in chronic kidney disease. Nephron. 2015;130(2):92–8.
167 Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):103–9.
168 Lee B, Moon KM, Kim CY. Tight junction in the intestinal epithelium: its association with diseases and regulation by phytochemicals. J Immunol Res. 2018;2018:2654656–5.
169 Kim HY, Yoo TH, Hwang Y, Lee GH, Kim B, Jang J, et al. Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD). Sci Rep. 2017;7(1):3057.
170 Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin. 2009 Aug;25(8):1919–30.
171 Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Dodi CB, Goldfarb DS, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther. 2010 Sep;27(9):634–47.
172 Miranda Alatraste PV, Urbina Arronte R, Gómez Espinosa CO, Espinosa Cuevas ML. Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp. 2014 Mar 1;29(3):582–90.
173 Wang IK, Wu YY, Yang YF, Ting JW, Lin CC, Yen TH, et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef Microbes. 2015;6(4):423–30.
174 Fagundes RAB, Soder TF, Grokoski KC, Benetti F, Mendes RH. Probiotics and chronic kidney disease: a systematic review. J Bras Nefrol. 2018 Jul–Sep;40(3):278–86.
175 Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonin system in a sex-dependent manner. Mol Psychiatry. 2013;18(6):666–73.
176 El Aidy S, Kunze W, Bienenstock J, Kleerebezem M. The microbiota and the gut-brain axis. Mol Neurobiol. 2015;52(6):3240–5.
177 Kwon HK, Li Y, Yun H, Zhang T, Huang Y, Zhou J, et al. Lactobacillus maintains healthy gut mucosa by producing L-Ornithine. Commun Biol. 2019;2(1):171.
178 Forsythe P, Inman MD, Bienenstock J. Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. Am J Respir Crit Care Med. 2007;175(6):561–9.
179 Atarashi K, Tanoue T, Shima T, Imaoka A, Kowalewska A, Morabito S, Fiaccadori E. Alterations of the gut microbiota in ESRD. Am J Nephrol. 2014;39(3):230–7.
193 Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372–85.

194 Laurans L, Venteclaf N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat Med. 2018;24(8):1113–20.

195 Evenepoel P, Meijers BK, Bammens BR, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl. 2009;76:S12–9.

196 Vanholder R, Scheipers E, Pletinck A, Nagler EV, Glorieux G. The Uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014;25(9):1897–907.

197 Chiara B, Giorgio G, Marco C, Manrico B, Claudio B, Pietro A. Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease. Current Drug Targets. 2015;16(4):366–72.

198 Hung SC, Kuo KL, Wu CC, Tarn DC. Indoxyl sulfate: a novel cardiovascular risk factor in chronic kidney disease. J Am Heart Assoc. 2017;6(2):e005022.

199 Yamaguchi J, Tanaka T, Inagi R. Effect of AST-120 in chronic kidney disease treatment: still a controversy? Nephron. 2017;135(3):201–6.

200 Finger EB, Bluestone JA. When ligand becomes receptor: tolerance via B7 signaling on DCs. Nat Immunol. 2002;3(11):1056–7.